# US 2016/0250346 A1 · Pyrrolobenzodiazepine-antibody conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250346 A1
- Document ID: US20160250346A1
- Status: Published application
- Kind: A1
- Application number: 15/028,591
- Filed: 2014-10-10
- Published: 2016-09-01
- Earliest claimed: 2013-10-11
- Assignees: MedImmune, LLC; Adc Therapeutics SA
- Applicants: Medimmune Limited; Adc Therapeutics SA
- Inventors: Philip Wilson Howard; Patricius Hendrikus Cornelis Van Berkel
- Web page: https://patentgrep.com/patent/US20160250346A1

## CPC

- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/68035: {the drug being a pyrrolobenzodiazepine}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Conjugates of specific PBD dimers with an antibody that binds to CD22, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 1.

## Claims

### Claim 1

A conjugate of formula
wherein:
Ab is an antibody that binds to CD22, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 1.

### Claim 2 (depends on 1)

The conjugate according to claim 1 wherein the antibody comprises a VH domain paired with a VL domain, the VH and VL domains having sequences of SEQ ID NO. 1 paired with SEQ ID NO. 2.

### Claim 3 (depends on 1)

The conjugate according to claim 1 wherein the antibody in an intact antibody.

### Claim 4 (depends on 3)

The conjugate according to claim 3 wherein the antibody comprises a heavy chain having the sequence of SEQ ID NO. 3 paired with a light chain having the sequence of SEQ ID NO. 4.

### Claim 5 (depends on 4)

The conjugate according claim 4 wherein the antibody comprises two heavy chains having the sequence of SEQ ID NO. 3, each paired with a light chain having the sequence of SEQ ID NO. 4.

### Claim 6 (depends on 1)

The conjugate according to claim 1 wherein the antibody is humanised, deimmunised or resurfaced.

### Claim 7 (depends on 1)

The conjugate according to claim 1 wherein the drug loading (p) of drugs (D) to antibody (Ab) is an integer from 1 to about 8.

### Claim 8 (depends on 7)

The conjugate according to claim 7, wherein p is 1, 2, 3, or 4.

### Claim 9 (depends on 7)

The conjugate according to claim 7 comprising a mixture of the antibody-drug conjugate compounds, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 2 to about 5.

### Claim at position 10

-12. (canceled)

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable diluent, carrier or excipient.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13 further comprising a therapeutically effective amount of a chemotherapeutic agent.

### Claim 15

(canceled)

### Claim 16 (depends on 13)

A method of treating cancer comprising administering to a patient the pharmaceutical composition of claim 13.

### Claim 17 (depends on 16)

The method of claim 16 wherein the patient is administered a chemotherapeutic agent, in combination with the conjugate.
